AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
Log in

NASDAQ:GMDAGamida Cell Stock Price, Forecast & News

$4.36
-0.12 (-2.68 %)
(As of 07/13/2020 10:14 AM ET)
Add
Compare
Today's Range
$4.36
Now: $4.36
$4.47
50-Day Range
$4.41
MA: $4.92
$5.75
52-Week Range
$2.60
Now: $4.36
$7.70
Volume11,065 shs
Average Volume176,092 shs
Market Capitalization$105.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMDA
CUSIPN/A
CIKN/A
Phone972-2659-5666

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.44 per share

Profitability

Net Income$-34,350,000.00

Miscellaneous

Employees79
Market Cap$105.60 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive GMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.

Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions

How has Gamida Cell's stock been impacted by COVID-19 (Coronavirus)?

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GMDA shares have increased by 3.1% and is now trading at $4.36. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gamida Cell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gamida Cell.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gamida Cell.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd (NASDAQ:GMDA) issued its quarterly earnings data on Thursday, May, 21st. The company reported ($0.31) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.12. View Gamida Cell's earnings history.

What price target have analysts set for GMDA?

7 brokerages have issued twelve-month price targets for Gamida Cell's shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Gamida Cell's stock price to reach $16.33 in the next year. This suggests a possible upside of 274.6% from the stock's current price. View analysts' price targets for Gamida Cell.

Has Gamida Cell been receiving favorable news coverage?

News headlines about GMDA stock have trended very negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gamida Cell earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Gamida Cell.

Are investors shorting Gamida Cell?

Gamida Cell saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 68,500 shares, an increase of 63.5% from the June 15th total of 41,900 shares. Based on an average trading volume of 327,300 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.3% of the company's stock are short sold. View Gamida Cell's Current Options Chain.

Who are some of Gamida Cell's key competitors?

What other stocks do shareholders of Gamida Cell own?

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the following people:
  • Dr. Julian Adams Ph.D., CEO & Director (Age 65, Pay $740k)
  • Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 44, Pay $353k)
  • Dr. Ronit Simantov, Chief Medical Officer (Age 55, Pay $587k)
  • Mr. Joshua D. Hamermesh MBA, Chief Bus. Officer (Age 48, Pay $508k)
  • Mr. Thomas J. Klima, Chief Commercial Officer (Age 48, Pay $392k)

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $4.36.

How big of a company is Gamida Cell?

Gamida Cell has a market capitalization of $105.60 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe.

What is Gamida Cell's official website?

The official website for Gamida Cell is www.gamida-cell.com.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.